FREE Case Evaluation: 1-800-375-6160
Zantac has been prescribed to treat conditions like heartburn and stomach ulcers, but like many medications, it can have a range of side effects. While the main health concern revolves around potential NDMA contamination, there are other side effects associated with its use. Here’s a list of some of these side effects:
Individuals who took Zantac and subsequently developed specific health issues, particularly certain types of cancer, may be eligible to file a Zantac lawsuit. The eligibility typically depends on the evidence linking the drug to the health condition, the duration of Zantac usage, and whether the individual was unaware of the potential risks. Those who can show that their health conditions were a direct result of consuming Zantac are most likely to be considered eligible.
The primary factor determining eligibility revolves around the medical evidence linking Zantac consumption to the development of specific health issues. The most frequently cited condition in these lawsuits is cancer, particularly cancers of the stomach, bladder, liver, and other organs.
Plaintiffs need to provide medical documentation to substantiate their claims that their health conditions are directly linked to their use of Zantac.
Another critical aspect of eligibility is the duration and dosage of Zantac intake. Individuals who took the drug at higher dosages might have a stronger case, as their exposure to potential contaminants like NDMA would be higher.
Additionally, being unaware of the potential risks at the time of consumption can also play a role, as the core of many lawsuits is the claim that manufacturers failed to provide adequate warnings about the drug’s risks.
Filing a Zantac lawsuit, like other personal injury or product liability claims, follows a series of steps to ensure the validity and strength of the claim. The following are the general steps to file a Zantac cancer lawsuit:
When Will Zantac Lawsuit Be Settled? Three generic Zantac manufacturers settled a case for $500,000 in 2022 before its scheduled trial in an Illinois state court. The plaintiff in the case alleged that the use of generic ranitidine had led to his esophageal cancer. This Zantac settlement came before what would have been the first Zantac-related cancer case to proceed to trial.
The resolution of this case might provide insight into how future cases in the Zantac MDL are handled as the bellwether trials approach.
GSK has agreed to several confidential settlements related to their lawsuits. Settlements were reached with Boyd/Steenvoord and David Browne for their Zantac cases just weeks before their trials were scheduled to commence.
The future of the Zantac litigation is contingent on the outcome of the Daubert hearing in Delaware, with Judge Vivian L. Medinilla's decision crucial for determining whether the case proceeds in this state. The appeal in the MDL is also critical, impacting the 14,389 plaintiffs in the MDL, while others not in the MDL may seek recourse in state courts.
Several Zantac cancer lawsuits in California, including one scheduled for trial and three bellwether cases, have been settled, with details remaining confidential. GlaxoSmithKline asserts that these settlements do not imply a wider strategy to resolve additional Zantac claims in state courts.
Numerous cases in the MDL have been dismissed, yet around 15,000 lawsuits are still under appeal. The 11th Circuit also received an appeal pertaining to the MDL.
A notable Zantac lawsuit trial is slated for November 13, 2023, to be held in a California state court.
After arbitration, Sanofi is not mandated to compensate Boehringer Ingelheim for Zantac lawsuits in the U.S. However, major pharmaceutical companies are still grappling with Zantac cancer risk and potential substantial settlements. Additionally, an impending Zantac lawsuit is marked for July 24, 2023, which could possibly change the litigation’s direction.
In Delaware, a procedural decision for 77,000 Zantac lawsuits has been made, introducing a specific trial to study Zantac’s ties to cancer. Meanwhile, the federal court saw Zantac lawsuits dismissed after specific hearings, while in Canada, a ruling found insufficient evidence linking Zantac to cancer. The appeal journey for Zantac cancer lawsuits, as indicated by an appeal notice to the 11th Circuit Court, is expected to be long.
A California state court judge allowed expert testimony linking Zantac to cancer for an upcoming trial. This first trial, eagerly watched by many, is now scheduled for July 24, 2023, especially after a series of dismissals from a federal judge.
February witnessed multiple developments in the Zantac cases: the anticipated trial concerning Zantac’s linkage to cancer was postponed to July 24, 2023. A California judge’s upcoming decision on the evidence linking NDMA in Zantac to cancer could reshape the landscape of Zantac lawsuits. However, the overall prospects for the Zantac lawsuits on appeal, especially concerning the MDL, appear to be bleak.
The start of the year saw New York consolidating some Zantac lawsuits into a class action, albeit on a limited scale. However, the pathway for registry appeals has been obstructed, complicating matters for plaintiffs aiming to maintain an appeal claim. Meanwhile, a pivotal motion in the MDL could change the fate of thousands of Zantac claims.
Defendants in a California Zantac lawsuit confirmed a confidential settlement. The Zantac MDL class action plans to appeal to the 11th Circuit Court of Appeals. A federal judge dismissed all Zantac claims in the MDL over lack of evidence connecting NDMA in Zantac to cancer.
Post-hearing, both sides of the Zantac lawsuit were permitted to submit supplemental briefs on the motion to exclude scientific evidence. Judge Rosenberg ordered more briefs about the admissibility of new expert witnesses and displayed concerns regarding plaintiffs’ causation experts.
Zantac trials are set for February 2023 in both California and Madison County, Illinois. A study found a significant link between ranitidine and various cancers. The plaintiffs accused Sanofi-Aventis of deleting key emails and requested a sanction.
Daubert hearings began to decide the inclusion of expert evidence in the Zantac class action lawsuit litigation, which could dictate the future of the Zantac class action lawsuits.
Lawsuits claim a variety of cancers are linked to Zantac, including stomach, liver, bladder cancer, kidney, esophageal, and colorectal cancer, among others.
In response to the concerns about NDMA contamination, many countries and regulatory bodies, including the U.S. Food and Drug Administration (FDA), recommended recalls and urged patients to consult their healthcare providers about alternative treatments.
The duration of a Zantac settlement can vary widely based on the specifics of the case, the number of plaintiffs involved, and the legal strategies employed by both sides. Some individual Zantac cases might reach a resolution relatively quickly, within months, while others, especially those that are part of large multidistrict litigation (MDL), can take several years.
With our assistance, locating a lawyer skilled in handling Zantac lawsuits is easy. Simply complete our contact form, and upon submission, a member of our team will promptly contact you to link you with a seasoned attorney tailored to your case. Reach out to us today without delay to secure the expert legal support and Zantac lawyer you need.
